ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022
October 31 2022 - 7:15AM
Business Wire
ADC Therapeutics SA (NYSE: ADCT) today announced that it will
host a conference call and live webcast on Tuesday, November 8,
2022 at 8:30 a.m. ET to report financial results for the third
quarter 2022 and provide business updates.
To access the conference call, please register here. Registrants
will receive the dial-in number and unique PIN. It is recommended
that you join 10 minutes before the event, though you may
pre-register at any time. A live webcast of the call will be
available under “Events and Presentations” in the Investors section
of the ADC Therapeutics website at ir.adctherapeutics.com. The
archived webcast will be available for 30 days following the
call.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage
biotechnology company improving the lives of those affected by
cancer with its next-generation, targeted antibody drug conjugates
(ADCs). The Company is advancing its proprietary PBD-based ADC
technology to transform the treatment paradigm for patients with
hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA® (loncastuximab
tesirine-lpyl) is approved by the FDA for the treatment of relapsed
or refractory diffuse large b-cell lymphoma after two or more lines
of systemic therapy. ZYNLONTA is also in development in combination
with other agents. Cami (camidanlumab tesirine) is being evaluated
in a pivotal Phase 2 trial for relapsed or refractory Hodgkin
lymphoma and in a Phase 1b clinical trial for various advanced
solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics
has multiple ADCs in ongoing clinical and preclinical
development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and
has operations in London, the San Francisco Bay Area and New
Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on Twitter and
LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221031005170/en/
Investors Eugenia Litz ADC Therapeutics
Eugenia.Litz@adctherapeutics.com +44 7879 627205
Amanda Loshbaugh ADC Therapeutics
Amanda.Loshbaugh@adctherapeutics.com +1 917-288-7023
Media Mary Ann Ondish ADC Therapeutics
maryann.ondish@adctherapeutics.com +1 914-552-4625
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Apr 2023 to Apr 2024